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ABSTRACT: Urinary volatile terpene (VT) levels are significantly altered with induced models of breast cancer in mice. The 
question arises whether VTs can detect efficacy of anti-tumor treatments. BALB/c mice were injected with 4T1.2 murine tumor cells 
in the mammary pad or iliac artery to model localized breast cancer and induced bone metastasis. The effect of two dopaminergic 
anti-tumor agents was tested by conventional histology and altered VT levels. The headspace of urine specimens was analyzed by 
gas chromatography-mass spectrometry. In the localized model statistical significance (p < 0.05) was identified for 26% of VTs and 
in the metastasis model, 19% of VTs. The authors discovered separate VT panels classifying localized/control (area under the curve 
(AUC) = 1.0), and metastasis/control (AUC = 0.98). Treatment samples were tested using these panels and showed that mice treated 
with either agent were statistically significantly different than cancer samples, which is consistent with conventional analysis.
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Globally, cancer is the second most frequent cause of death after heart disorders. In 2020, over 30% of the estimated new 
cancer cases in women in the United States will be breast cancer and 15% of the estimated cancer related deaths in women will be 
caused by breast cancer1. Comprehensive breast cancer research has demonstrated its heterogeneous nature2–4 through 
immunohistochemical markers and gene expression profiling5. Due to distinct tumor characteristics, cancers respond differentially to 
traditional treatments, making the “one model fits all” strategy imperfect. The growing knowledge about complexities of breast cancer 
pathogenesis demand tailoring personalized systemic and regional therapies to increase efficacy and decrease unnecessary morbidity6. 
Monitoring therapeutic effect can aid in patient decision-making throughout treatment and potentially help clinicians advance 
personalized medicine. 
Molecular based methods for monitoring disease progression could include analysis of DNA7, RNA8, proteins9–12,  volatile 
organic compounds (VOCs)13 and other metabolites14–16. VOCs are intermediates or final products of metabolic pathways and can 
provide potential information about disease14. They report not only intratumoral metabolism but also interactions between the tumor 
and its microenvironment17. VOCs are analyzed non-invasively from samples of urine, sweat, breath or other biological samples18–20. 
Different VOC biomarkers for various diseases have been proposed in previous studies21–28. It is anticipated that changes in VOC 
concentrations induced by cancer can be restored by therapeutic agents while their corresponding effect can be morphologically 
observed by measuring tumor size/weight.  
Currently we are aware of no clinically established biomarkers solely dedicated for examining treatment effect for breast 
cancer. Diagnostic tests are usually extended for tracking therapeutic responses and corresponding tumor growth29. One of the 
common ways of assessing tumor size is through physical examination, but often results in incorrect prognosis30. Moreover, imaging 
methods such as PET, MRI and X-rays are expensive and have limitations in analyzing treatment induced morphological changes31,32. 
In addition, frequent use of these methods pose a potential harm of exposure to radiation31. Lastly, the evaluation of tumor size due 
to therapies is quantifiable only after about 6-8 weeks of treatment33, which may be after the patient has received potentially harmful 
radiation/therapy for a prolonged period. Recent studies involving blood analysis of circulating tumor cells (CTCs) unveil a promising 
tool for determining treatment efficacy34,35. However, these studies may overlook the probability of clonal hematopoiesis36. 
Traditional metabolomic assays have identified potential markers for therapeutic efficacy37,38, but efforts largely remain untargeted.
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The authors previously reported that urinary VOC panels primarily comprised of volatile terpenes (VTs) were able to 
differentiate tumor-bearing mice from healthy control mice by headspace analysis coupled to gas chromatography-mass spectrometry 
quadrupole time-of-flight (GC-MS QTOF) and that a separate panel could differentiate between mice injected with tumors in the 
mammary pad from those injected in the bone39. Herein, the study is extended to determine if urinary VTs can non-invasively predict 
the effect of therapy on the tumor. The efficacy of two FDA approved agents involved in dopaminergic signalling, Trifluoperazine 
(TFP) and Fluphenazine (FP), were previously analyzed by CT, X-ray imaging and histological analysis of tumor size and weight40. 
Concurrently, urine was collected to understand the effect of these treatments on VT composition and corresponding correlation with 
metabolic pathways. This study demonstrates a novel approach through targeting VTs, by-products of the mevalonate pathway which 
has no known direct effect on dopaminergic metabolism, to detect cancer and monitor the efficacy of TFP and FP in mice. 
EXPERIMENTAL SECTION
Materials and Reagents
Female BALB/c mice (~ 6 weeks of age) were purchased from Harlan Laboratories, Indianapolis, IN, USA. 4T1.2 tumor 
cells were obtained from Dr. R. Anderson at the Peter MacCallum Cancer Institute. Trifluoperazine dihydrochloride was purchased 
from Enzo (Cat. number: ALX-550-310-G001) and Fluphenazine dihydrochloride was purchased from Sigma Aldrich. Human urine 
standards were obtained from UTAK Laboratories, California. Two-centimeter polydimethylsiloxane/carboxen/divinylbenzene 
(PDMS/CAR/DVB) solid phase microextraction (SPME) fibers manufactured by Supelco and 8M Guanidine Hydrochloride 
(pH=8.5) were purchased from Sigma Aldrich. 10 mL headspace vials and 18 mm magnetic lids were purchased from Thermo 
Scientific. SPME Injection Sleeves were purchased from Sigma Aldrich (ID: 0.75 mm). A 7890A GC system coupled to an Agilent 
7200 Accurate-Mass QTOF MS system with a PAL autosampling system (CTC Analytics) was used to analyze VOCs. The column 
utilized was an Agilent HP-5ms, 5% phenyl methyl siloxane GC column of 30 meters in length, 250 μm internal diameter and 0.25 
μm film thickness. MATLAB (R2018b; Math Works) was used to generate hierarchical heatmaps and Origin (OriginLabs, 2018) was 
utilized for principal component analysis (PCA) mapping to visualize patterns in the data.
Tumor Cell Injection and Treatment
In the localized tumor model, 4T1.2 cells (5.0 × 105 cells in 50 l PBS) were subcutaneously injected into the mammary fat 
pad of BALB/c female mice. These were further classified into three groups with mice receiving vehicle control (PBS solution) and 
mice treated with TFP and FP (1mg/kg body weight). Agents were administered every day at the site of tumor cell injection, and mice 
were sacrificed on day 18. For the induced bone metastasis tumor model, BALB/c female mice were injected with 4T1.2 cells (1.0 × 
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105 cells in 50 l PBS) in the right iliac artery.  One group received vehicle control (PBS solution) while the agents TFP and FP were 
given to the other two groups via intra-peritoneal injection (2mg/kg body weight), and all mice were sacrificed on day 17. Normal 
control urine was collected from the mice prior to injection with tumor cells. Urine collection was performed in two time periods, 
with the first time period collecting from mice injected with tumor cells in the mammary pad and the second from mice injected in 
the iliac artery40. A whole-body X-ray image was taken using a Faxitron radiographic system (Faxitron X-ray Co., Tucson, AZ, USA). 
Urine Collection and Sample Preparation
All experimental procedures followed the Guiding Principles in the Care and Use of Animals supported by the American 
Physiological Society and approved by Indiana University Animal Care and Use Committee. Mice were housed in glass cages at 
room temperature (25˚C) and fed the same diet (mouse-chow ad libitum). Mice were moved to a cage covered in parafilm and urine 
was collected using pre-cleaned glass Pasteur pipettes into pre-cleaned 10 mL glass headspace vials over dry ice and stored in a -
80˚C freezer prior to GC-MS QTOF analysis. Urine aliquots of 75 μL were prepared from each sample and 8M guanidine 
hydrochloride (GHCl) was added in a 1:1 ratio at room temperature one hour before GC analysis. 
SPME and GC-MS QTOF
Methods for effective headspace analysis of VOCs in mouse urine differs slightly from analysis of human urine. Mouse 
urine contains major urinary proteins (MUPs) that sequester VOCs in hydrophobic pockets41.  A common denaturing agent is GHCl41 
and was utilized herein. Urine was heated and agitated at 250 rpm and 60˚C for 30 minutes in a 10 mL vial to release VOCs into the 
sample headspace. Next, the pre-conditioned SPME fiber was inserted through the septum of the vial for a 30-minute incubation 
period at the same temperature and agitation rate to concentrate VOCs from the headspace. The fiber was conditioned at 260 ˚C for 
ten minutes prior to the first sample every day, and 4 minutes between runs. After incubation, the SPME fiber was inserted into the 
GC inlet at 250 ˚C for two minutes to thermally desorb VOCs. The chromatographic protocol involved the oven temperature 
maintaining 40 °C for 2 minutes followed by a ramp to 100 °C at a rate of 8 °C/min, 15 °C/min ramp to 120 °C, 8 °C/min to 180 °C, 
15 °C/min to 200°C and finally an 8 °C/min ramp to 260 °C. Due to the limited amount of urine collected from each mouse, only one 
aliquot was analyzed for each sample. Controls of standard urine (UTAK Laboratories) were run daily and demonstrated reproducible 
measurements over the course of the experiment. The mass spectrometry data have been deposited to the Chorus Archive 
(https://chorusproject.org/pages/dashboard.html#/projects/all/1639/experiments) with the data set identifier 1639: Breast Cancer 
Volatile Biomarker Discovery in Mice.
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Data Pre-processing and Pre-treatment
GC-MS QTOF data was collected utilizing Agilent Mass Hunter software in centroid format. Deconvolution and spectral 
alignment of chromatographic peaks across all samples based on similarities of mass-to-charge (m/z) ratios and retention times was 
performed using Mass Hunter Quantitative Profinder (version B.08.00). A matrix of compounds with integrated signal values and 
retention times for every sample was generated. Silica-based VOCs were removed from the data matrix as these are characteristic of 
SPME fiber and column degradation products. MS Total Useful Signal (MSTUS) was calculated using the remaining compounds and 
applied to normalize the data and remove unwanted variation between samples42. MSTUS vales were auto-scaled (z-scored) to obtain 
a similar range of signals for all VOCs in the sample matrix. 
Univariate Analysis
The two data sets were tested for Gaussian distributions using skewness and kurtosis with the accepted limits of less than 
1.9643,44. Univariate analysis was performed as a filter45 using a two-tail Student’s T-test (p-value < 0.05) on the VOCs present in at 
least 60% of at least one sample class to screen for VOCs differentially excreted between cancer and control sample classes. The log2 
Fold Change of metabolites between the cancer and control sample groups was plotted against statistical significance to generate 
volcano plots for both comparisons (localized/control and metastasized/control)46. Hierarchical clustering was undertaken to visually 
observe cancer induced changes in VOC concentrations. Hierarchical heatmaps were created by z-scoring MSTUS values for each 
VOC across all samples47. Compounds are grouped on the y axis based on their similarities in terms of VOC signals across all samples. 
Euclidean distance metrics and average linkages were utilized to generate the hierarchical tree. 
Compound Identification
VTs and VOCs with p-value < 0.05 were identified using Mass Hunter Quantitative Profinder and Mass Hunter Unknown 
Analysis (version B.08.00) integrated with the NIST14 mass spectral library. Compounds in Profinder were found in Unknown 
Analysis using average retention times and mass spectra. Features identified with a match factor higher than 65 from the NIST library 
were initially identified. Preliminary confirmation of these compounds was performed by comparing the non-polar retention index 
(NPRI) given in NIST to an experimental NPRI calculated from the average retention time using an instrument specific curve 
developed using standards. If the theoretical and experimental NPRI values were within the range of 75 units, the compound was 
deemed tentatively identified. Multivariate analysis was only performed on VTs with a match factor of at least 70. Identified VTs 
were further categorized into three groups: (1) VTs identified and confirmed by SPME GC-MS analysis of pure standards, (2) VTs 
identified with NPRI deviation < 5% and (3) VTs identified with > 5% but < 10% deviation in NPRI. All VTs identified in this study 
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are listed and grouped in Supplementary Table S1 with their difference in NPRI (ΔNPRI), retention time (RT), top three m/z peaks 
and match factor provided by NIST. The preliminary identification of isoprene and limonene was verified by running pure standards.
Multivariate Analysis
PCA was performed using all VOCs with p-value < 0.05 between cancer and control sample groups to visualize global 
patterns and sample outliers48,49. In contrast, based on the previous research highlighting the dysregulation of the mevalonate pathway 
in cancer, only VTs were used to develop panels discriminating between cancer and no-cancer. The matrix of VTs was analyzed 
using forward feature selection49 coupled with Linear Discriminant Analysis (iterative LDA) to distinguish between cancer and 
control groups. The panel producing maximum distance between the cancer and control samples via iterative LDA was selected until 
the panel gave perfect separation between groups (area under the receiver operating characteristic (AUROC) equal to one). Leave 
one out cross validation (LOOCV) was performed to test if the classification models are overfit50. The Variation Inflation Factor 
(VIF) was calculated to assess the degree of multicollinearity present in each classification model51. A VIF threshold value of 10 was 
employed to indicate a high degree of multicollinearity between predictor and response values52. Samples receiving treatment were 
tested to determine if the classification model could predict the efficacy of TFP and FP. Primary LDA scores separating cancer/control 
sample classes were used to quantify the effect of treatments. One-tail T-tests were performed on LDA scores to determine if there 
was a statistical difference between the two treatments and control/cancer sample classes.
RESULTS AND DISCUSSION
X-ray and Histological Analysis and Urine Collection
In a related study, the results of which were reported previously40, 24 BALB/c mice were injected with 4T1.2 cells in the 
mammary fat pad, eight of which received no treatment, eight received the FP treatment agent and the other eight received the TFP 
treatment agent. A different set of 23 mice were injected with 4T1.2 cells in the iliac artery and seven received no treatment, nine 
received FP and seven received TFP. From these mice, 58 urine samples were collected (see Table 1) and analyzed by GC-MS QTOF 
as described to identify potential breast cancer VT biomarkers and determine their ability to monitor therapeutic efficacy of TFP and 
FP. For the localized model, tumors from treated and untreated mice were weighed and measured in size. Tumors injected in the 
mammary pad were significantly lighter and smaller in mice treated with TFP or FP relative to untreated mice (results previously 
published)40. For the bone metastasis model, a whole-body X-ray image was taken prior to euthanasia (Figure 1).  Compared to the 
normal control, the placebo without any treatment presented bone damages in the distal femur and the proximal tibia. However, 
administration of FP and TFP suppressed tumor induced bone damages. The previously published analysis was conducted via CT 
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and showed tumor bearing mice treated with TFP or FP had increased trabecular bone thickness. Mechanical testing also showed that 
mice receiving treatment had increased femur stiffness40.
Data Screening and Univariate Analysis
Translating urine samples to potential volatile biomarkers starts by deconvoluting sample chromatograms and aligning 
VOCs across all samples. This process generated a matrix comprising a total of 215 VOCs (27 VTs) present in 60% of at least one 
sample class in the localized model and a matrix comprised of 370 VOCs (36 VTs) for the induced bone metastasis model. The data 
had a normal distribution with z-score values for skewness and kurtosis within the accepted limits. Volcano plots for both cancer 
models (localized/control and metastasized/control) can be observed in Figure 2 (a) and (b). Student’s T-test alone gave a total of 24 
VOCs with p-value < 0.05 between control and localized samples (17 upregulated and 7 downregulated) and 30 between control and 
metastasized samples (9 upregulated and 21 downregulated). Due to the specific focus on terpenes, VTs differentially excreted with 
a p-value < 0.05 are listed in Table 2. The Table contains, for each VT: an abbreviation, a colloquial name and IUPAC name, CAS 
ID, p-value, regulation in cancer samples and the model of cancer the VT was detected in. VTs in Table 2 can be observed on the 
volcano plots with their associated abbreviation in red (upregulated in cancer) or green (downregulated in cancer). 12 of the 14 VTs 
reported in Table 2 were detected in 100% of at least one sample class (control or cancer). The other two VTs (safranal and geranial) 
were detected frequently in cancer samples (> 85%) and were largely depleted in control samples (≤ 20%).
To illustrate trends showing variations in individual samples, hierarchical clustering of all VOCs with p-value < 0.05 was 
undertaken. Heatmaps for both models of cancer are shown in Figure 3(a) and (b). VTs with p-value < 0.05 are identified on the y-
axis using their abbreviations in Table 2. It can be observed in the localized model (Figure 3(a)), four VTs are upregulated in breast 
cancer and three are downregulated. Even though more terpenes were identified as upregulated in the cancer sample class, the 
upregulated VTs have higher intraclass variation when compared to downregulated terpenes. For the bone metastasized model, five 
terpenes are downregulated and two are upregulated. VTs both up and downregulated in the metastasized model show low intraclass 
variation and high interclass variation between cancer and control samples (Figure 3(b)). Individual VTs and VOCs with p-value < 
0.05 were analyzed to identify if any single VOC could separate cancer and control samples. For both models of cancer, a single 
volatile was able to perfectly differentiate between control and cancer samples (Figure 4). 3-ethyl-2,5-dimethylhexa-1,3-diene 
(abbreviated as HEX in Table 2) discriminated between localized cancer and control samples. Figure 4(a) depicts a box/whisker plot 
of normalized signals for HEX in control, cancer and treatment sample classes. However, treatment samples (FP and TFP) 
demonstrated a statistically significant difference relative to control and no difference when compared to the cancer sample class, 
suggesting HEX alone was an imperfect reflection of histological data. In the bone metastasis model of breast cancer, 1,3-octadiene 
perfectly distinguished cancer and control samples (Figure 4(b)). In this case, TFP but not FP was significantly different than the 
cancer sample class, and both were different relative to control. The two VOCs in Figure 4(a) and (b) perfectly distinguish cancer 
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and control, but do not reflect the morphological and X-ray analyses which showed that both treatments had a significant inhibitory 
effect on tumor growth. This suggests a multivariate approach should be utilized.
Multivariate Analysis
Multivariate analysis can be used to identify outliers efficiently, visualize data patterns, and quantify trends observed in 
multiple compounds filtered by univariate analysis. PCA was implemented using all the compounds with p-value < 0.05 (Student’s 
T-test) to visualize global patterns and identify any potential sample outliers: both PCA plots demonstrated absence of sample 
outliers (Supplementary Figure S1). Supervised multivariate techniques were employed to find a set of VTs with the highest 
classification accuracy between control and cancer samples. Terpenes, precursors of cholesterol and steroids, were identified as 
potential biomarkers both in the localized and metastasized tumor models. These results are consistent with our previous 
experiment conducted for identifying tumor site specific VOCs39. Following Xia et al., knowledge and data driven based feature 
selection methods were utilized for iterative LDA53 by using all 27 VTs related to the mevalonate pathway. A panel of three VOCs 
(d-limonene, safranal and ocimene) distinguished between localized and no cancer samples with an AUROC of 1.0. A graphical 
representation of this panel, LDA-Local, can be seen in Figure 5(a). LOOCV was utilized to test if the classification model was 
overfit, and it produced an estimated AUROC of 1.0. The VIF calculated for predictor and response values was 4.55 (low), 
demonstrating non-collinearity. When tested, the co-clustering of treated samples was quantified by the primary LDA scores 
depicted in Figure 5(a) and can be seen in Figure 5(c). Both treatments (TFP and FP) clustered in between cancer/control samples 
and were statistically different than cancer in the direction of control samples, indicating an intermediate response reflective of the 
morphological analysis. VOCs did not predict the treated mice were particularly healthy, however. LDA scores of FP treated 
samples were statistically significantly different than control samples in the direction of cancer, and TFP was not statistically 
different than control but had a p-value = 0.057. 
For the metastasized model, forward feature selection was performed on all 36 VTs in a similar fashion. Five LDA 
classification models were built and all separated control and cancer perfectly (AUROC = 1.0). The model chosen to test treatment 
samples had the highest LOOCV AUROC and consisted of the VTs most frequently selected by the algorithm or compounds 
detected in the most samples. The panel chosen, LDA-Meta, consisted of three VTs (irone, bisabolene and geranial) and provided 
perfect classification of control and metastasized samples (Figure 5(b)). LOOCV was applied and produced an AUROC of 0.98, 
demonstrating the model is not overfit. The VIF calculated for predictor and response values was 2.0, demonstrating non-
collinearity. Treatment samples were tested using this panel and clustered in between cancer/control samples. The primary LDA 
scores were analyzed and both treatments were statistically significantly different than cancer in the direction of control, and control 
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in the direction of cancer (Figure 5(d)). This demonstrates an intermediary response in VTs which is consistent with the degree of 
tumor induced bone damages depicted in the X-ray analysis in Figure 1(a) and (b).
Metabolic Interpretation
One of the hallmarks of cancer is its deregulation of cellular energetics by manipulating metabolic pathways54. A unique 
finding of this study is the relatively large number of terpenes in VOCs with p-value < 0.05 between control and cancer groups: of 
63 VTs found, 14 or almost one quarter were statistically different between control and cancer groups. VT biosynthesis is a 
descending step of the mevalonate pathway and a precursor to cholesterol synthesis. A plethora of terpenes are synthesized from the 
reactions between geranyl pyrophosphate (GPP) and farnesyl pyrophosphate (FPP), which produce the building blocks of steroids. 
Figure 6 illustrates the bone metastasis tumor injection model leading to the dysregulation of the mevalonate pathway and 
differential expression of urinary VTs. Figure 6 defines some, but by no means all the VTs downstream of GPP in the mevalonate 
pathway that have been identified in Table 2 as potentially useful to detect cancer. VTs are also produced by plants and in general 
present a problem as potential interferents because they are found in food. This might provide a challenge for human urine analysis 
but could be overcome by subjects avoiding food with high VT content prior to donating urine. In this study however, all mice were 
fed the same diet (mouse-chow ad libitum) and were kept in the same environment. No significant difference in food consumption 
was observed between control, tumor-bearing and treated mice, but it is a limitation of this study that mouse-chow food 
consumption was not tracked precisely and analysis for VT content of mouse-chow is not included. Differentially excreted 
compounds presented in Figure 2 and 3 include 2, 5-ditert-butylcyclohexa-2, 5-diene-1, 4-dione, p-menth-3-ene, limonene, 
pelargonic acid and decanal, which are known to be involved in the lipid peroxidation metabolic pathway22,55,56. 
There is an intriguing link between VTs as markers of cancer and potential treatments for cancer. For example, terpenes 
and terpenoids are known to have inhibitory action against cancer57,58 and cholesterol itself has previously been reported to play a 
role in the development of certain cancers59. In a different study, the current authors correlated the dysregulation of urinary VTs to 
the upregulation of cholesterol in mice60. This is significant as both VTs and cholesterol are end- or byproducts of the mevalonate 
pathway. The authors acknowledge VTs may also be presenting themselves in the form of glucuronides as studies have shown the 
glucuronidation of exogenous terpenes61. VTs endogenously synthesized as cancer-related byproducts will, even if partially 
glucuronidated, also be excreted in the free form and may therefore be considered potential biomarkers. For example, Silva et al. 
detected 4-carene as a potential biomarker for breast cancer22 and Khalid et al. detected dihydromyrcenol as a marker for prostate 
cancer in human urine62, both in the free form.
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Any drug treatment would be expected to cause a change in mouse urine, including a change in expressed VOCs. To 
narrow the focus from untargeted analysis of VOC differences caused by drug treatments, this research focused on VTs that are by-
products of the mevalonate pathway which is known to be dysregulated by cancer63. Our previous publication implicated many VTs 
as potential biomarkers of breast cancer, which allowed us to target them to build models for classification in this assay. Through 
targeted feature selection, strong and stable models were built using biologically relevant features. An added benefit of analyzing 
VTs is that there is no known direct relationship between Fluphenazine and Trifluoperazine and the mevalonate pathway, although 
a previous report on the effect of Fluphenazine as a treatment for mammary carcinoma in rats showed a decrease in cholesterol and 
an increase in cholesterol esters64. An unrelated report showed that extended administration of Trifluoperazine caused a significant 
rise in serum cholesterol in rabbits65. These may demonstrate indirect relationships of these agents with the mevalonate pathway.
CONCLUSION
The results from this study correspond to the findings found in previous work for breast cancer in mice models and extend 
the use of the potential VT biomarkers to monitor therapeutic efficacy of Trifluoperazine and Fluphenazine. Many of the potential 
biomarkers found in the previous work39 belonged to the mevalonate or lipid peroxidation metabolic pathway and are reported in 
this study. For the mammary pad model, nine of the VOCs with p-value < 0.05 were previously reported, including limonene, 
isoprene (previously identified as penta-1,4-diene), 1-octen-3-one and kusol (1,2,3,4-tetrahydroquinoline). Six of the volatiles that 
were identified with p < 0.05 in the bone model were previously identified as potential biomarkers (1-octen-3-ol, bisabolene, 2-
hexanone, 2-pentanone, 2-ethyl-2-hexenal and 4,5-dimethyl-4-hex-en-3-one). Similar and discrete results are expected in this study 
because mice injected in the mammary pad were compared to control mice independent of mice injected in the bone and mice 
injected in the bone were analyzed independent of mice injected in the mammary pad. This study lays out a potential method for 
analyzing effects of cancer therapy by testing VTs in urine. However, the results are based on a small number of mice all fed the 
same chow and infected with the same tumor cells. Furthermore, SPME GC-MS assays are the golden standard for analyzing VOCs 
but are not appropriate for analyzing larger hydrophilic molecules including glucuronidated VTs which are better analyzed using 
other MS-based methods. It is anticipated it would be very beneficial to extend this promising approach to more heterogeneous 
samples and larger data sets. Optimization of urine collection/preparation and analytical techniques may improve the identification 
and discovery of VT biomarkers in patient samples.
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Table S1. Volatile Terpenes reported in this study with percent differences in NPRI, retention time (RT), top three m/z peaks and NIST 
match factor.
Figure S1. Principle Component Analysis of statistically significant (p-value < 0.05) VOCs in control, tumor and treatment models for (a) 
localized and (b) metastasized breast cancer.
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Table 1. Number of mice from each model of breast cancer









Induced bone metastasis 
(metastasized)
Trifluoperazine 7
Table 2. Chemical names of volatile terpenes with p-value <0.05 for both cancer models
Abbreviation IUPAC (Common Names) CAS ID P-value Regulation Cancer Model
LIM (4R)-1-methyl-4-prop-1-en-2-ylcyclohexene (Limonene) 5989-27-5 0.013 down Localized
SAF 2,6,6-trimethylcyclohexa-1,3-diene-1-carbaldehyde (Safranal) 116-26-7 0.014 up Localized
MEN 4-methyl-1-propan-2-ylcyclohexene (p-Menth-3-ene) 500-00-5 0.015 up Localized
HEX 3-ethyl-2,5-dimethylhexa-1,3-diene 61142-36-7 0.017 up Localized
BIC 1-methoxy-4-methylbicyclo[2.2.2]octane 6555-95-9 0.021 up Localized
ISO 2-methylbuta-1,3-diene (Isoprene) 78-79-5 0.032 down Localized
ISA 2-methylbut-3-en-2-ol (Isoprenyl Alcohol) 115-18-4 0.044 down Localized
CRY 4-propan-2-ylcyclohex-2-en-1-one (Crypton) 500-02-7 0.009 down Metastasized
THU 2-hydroxy-5-propan-2-ylcyclohepta-2,4,6-trien-1-one (Thujaplicin) 672-76-4 0.013 down Metastasized
GER 3,7-dimethylocta-2,6-dienal (Geranial) 141-27-5 0.013 up Metastasized
BIS 1-methyl-4-(6-methylhepta-1,5-dien-2-yl)cyclohexene (Bisabolene) 495-61-4 0.014 down Metastasized
IRO 4-(2,5,6,6-tetramethylcyclohex-2-en-1-yl)but-3-en-2-one (Irone) 79-69-6 0.031 down Metastasized
NER 3,7-dimethylocta-2,6-dien-1-ol (Nerol) 106-25-2 0.036 up Metastasized
CYU 1,5,9,9-tetramethylcycloundeca-1,4,7-triene NA 0.037 down Metastasized
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Figure 1. X-ray images of the distal femur and proximal tibia in the bone metastasis model for the left
hindlimb (a) and the knee (b). The red arrows in (a) and red circles in (b) indicate tumor-induced bone
damages, and the knee images are shown in two X-ray levels (low and high).
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Figure 2. Volcano plots for (a) control/localized and (b) control/metastasized tumor models with negative 
log of p-value from Students T-test plotted as a function of log2 Fold Change (VTs in Table 2 with p-
value < 0.05 are labeled and highlighted in green or red).
Page 19 of 23
ACS Paragon Plus Environment






























































Figure 3. Hierarchical clustering of VOCs with p-value < 0.05 in control and tumor samples to visualize 
and observe the change in concentration for (a) localized and (b) metastasized models of breast cancer. 
VTs with p-value < 0.05 are labeled using their corresponding abbreviation in Table 2.
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Figure 4. Box and whisker plots using normalized signals for (a) 3-ethyl-2,5-dimethylhexa-1,3-diene in 
the localized model and (b) 1,3-octadiene in the metastasized model of breast cancer (average values are 
colored squares and sample outliers are black diamonds).
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Figure 5. Linear discriminant analysis (LDA) plot (a) utilizing limonene, safranal and ocimene to 
discriminate localized and control sample classes and test treatment samples and (b) using irone, 
bisabolene and geranial to separate metastasized/control samples and test treated urine. Box/whisker plots 
of the primary LDA scores for all sample classes in the (c) localized model and (d) bone metastasis model 
(average values are colored squares and sample outliers are black diamonds). 
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Figure 6. Schematic of murine tumor cell injection leading to the dysregulation of the mevalonate pathway 
highlighting VTs identified as altered in the localized tumor model (limonene and isoprene) and in the 
metastasized tumor model (bisabolene and geranial). (MVA = mevalonate, HMG-CoA = 5-hydroxy-3- 
methylglutaryl-coenzyme A reductase)
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